Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ERS Genomics
ERS Genomics
Activities:
Manufacturing
Research & Development
Analysis
X
LinkedIn
Trending Articles
How advanced technologies are unlocking the future of drug manufacturing
As the drug production landscape changes, it opens the door to pursue hybrid opportunities that push the boundaries of technological advancement in the field, reports Jon...
Actylis and Novo Nordisk Pharmatech partner for the distribution of benzalkonium chloride
The two companies aim to expand the distribution of benzalkonium chloride within Europe
Upperton opens novel development and GMP manufacturing facility
The novel 50,000 sqft development and GMP manufacturing facility in Nottingham contains ten GMP manufacturing suites, quality control laboratories and formulation development...
Astellas begins construction of manufacturing site in Tralee
600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Policy vacuum risks UK becoming a medicines supply backwater
The UK becoming a "backwater" supply marker could jeopardise £18bn of NHS savings from newly off-patented drugs during the next five years
Upcoming event
BioProcess International Europe
9-12 April 2024 | Exhibition | RAI Amsterdam
See all
Related Content
Cell & Gene Therapy
CRISPR patent upheld by CNIPA
Patent CN201380038920.6 was upheld by the China National Intellectual Property Administration (CNIPA) in response to an invalidation challenge
Regulatory
Key Charpentier/Doudna CRISPR patent upheld by Japanese Patent Office
Patent JP6692856 upheld for second time in response to invalidation challenge
Research & Development
CET licenses CRISPR/Cas9 portfolio from ERS Genomics
ERS was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr Emmanuelle Charpentier
Finance
ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement
ERS Genomics holds an exclusive license from Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Regulatory
ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement
ERS Genomics holds the exclusive license from co-founder Dr Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform
Regulatory
ERS Genomics licenses CRISPR gene editing tech to Otsuka
Summit Pharmaceuticals International Corporation, a subsidiary of Sumitomo Corporation, serves as the exclusive agent for ERS Genomics in Japan
Finance
ERS Genomics appoints Jon Kratochvil as VP Business Development
He is an inventor on more 40 patents and patent applications
Subscribe now